Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market In The Coming Years?

In recent times, the market size of alpha-1 antitrypsin deficiency augmentation therapy has experienced robust growth. The market forecast indicates a rise from $1.69 billion in 2024 to $1.8 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.2%. This substantial growth in the historical period is largely due to enhanced diagnosis methods, awareness initiatives, clinical studies, and an increasing elderly population.

It is predicted that the alpha-1 antitrypsin deficiency augmentation therapy market will witness significant expansion over the coming years. The market value is projected to reach $2.44 billion by 2029 with a compound annual growth rate (CAGR) of 7.9%. This considerable growth in the forecast period is due to developments in telehealth, remote monitoring methods, precision medicine and gene therapy. The trends to look out for during this period include data on long-term safety and effectiveness, patient-centric care models, tele-rehabilitation schemes and individualized dosing regimens.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp

What Drivers Are Accelerating Expansion Of The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

The rise in respiratory diseases is propelling the expansion of the alpha-1 antitrypsin deficiency augmentation therapy market. These diseases negatively impact the lungs and overall respiratory system, causing breathing issues and reduced lung functionality. The goal of alpha-1 antitrypsin deficiency augmentation therapy is to address these diseases by increasing levels of the deficient protein found in individuals with alpha-1 antitrypsin deficiency. The therapy helps by adjusting the protease-antiprotease activity in the lungs, safeguarding lung tissue from damage due to excess neutrophil elastase activity, and mitigating inflammation. For instance, in March 2023, the US-based national public health organization, the Centers for Disease Control and Prevention, reported that there were 8,300 tuberculosis (TB) cases in the United States in 2022, an increase from 7,874 cases in 2021. Consequently, the rising prevalence of respiratory diseases is fueling the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

How Is The Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Broken Down By Segment?

The alpha-1 antitrypsin deficiency augmentation therapymarket covered in this report is segmented –

1) By Product Type: Glassia; Aralast NP; Prolastin C; Zemaira And Respreeza

2) By Route Of Administration: Oral; Injection; Inhalation

3) By End User: Hospitals; Specialty Clinics; Other End Users

Which Notable Trends Are Transforming The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Outlook?

Leading firms in the acute respiratory distress syndrome (ARDS) market are prioritizing the advancement of unique therapies, such as drug development based on recombinant technology, to maintain their market standing. Recombinant DNA technology, which involves altering the DNA of live organisms to produce specific proteins, plays a crucial role in producing therapeutic pharmaceuticals. In March 2022, for example, the US-based biotech firm Inhibrx Inc. declared that INBRX-101 received an orphan drug designation from the U.S. Food and Drug Administration (FDA) for alpha-1 antitrypsin deficiency (AATD) treatment. This recombinant human AAT-Fc fusion protein has the potential for once-monthly usage and aims to safely achieve and sustain the AAT levels seen in healthy individuals.

Which Firms Are Making The Biggest Impact In The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13006&type=smp

Browse Through More Reports Similar to the Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market 2025, By The Business Research Company

Tnf Alpha Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tnf-alpha-inhibitor-global-market-report

5 Alpha Reductase Deficiency Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/5-alpha-reductase-deficiency-global-market-report

Alpha Glucosidase Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model